DBV Technologies SA, of Bagneux, France, said the FDA accepted an investigator-sponsored investigational new drug (IND) application for a phase IIa trial for the treatment of milk-induced eosinophilic esophagitis (EoE) in children using the company's patch therapy Viaskin Milk.